Study guide

18.2 Records Retention and Archiving

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

18.2 Records Retention and Archiving

Key Takeaways Explain This Topic AI

FDA regulations (21 CFR 312.62) require investigators to retain records for a period of 2 years following the date a marketing application is approved, or 2 years after the investigation is discontinued.

ICH E6(R3) requires essential records to be retained for the required period under applicable regulations or until the sponsor says they are no longer needed, whichever is longest.

Trial sponsors often impose longer contractual retention requirements and tell the site in writing when records are no longer needed.

Archiving facilities must provide protection from environmental damage (fire, water, pests) and ensure strict access control.

Last updated: October 2026

The Importance of Records Retention

In clinical research, the old adage "if it wasn't documented, it wasn't done" is only half the story. The full truth is: "if it wasn't documented, and the document isn't securely retained, it wasn't done." Records retention is the practice of maintaining trial-related documents for a specified period after the study has closed. These records are vital for regulatory inspections, verifying trial data integrity, and supporting future medical research.

Regulatory Frameworks for Retention

The Clinical Research Coordinator (CRC) must navigate a complex web of retention requirements dictated by federal regulations, international guidelines, institutional policies, and sponsor contracts.

FDA Regulations (21 CFR 312.62)

For studies conducted under an Investigational New Drug (IND) application, the US Food and Drug Administration (FDA) requires investigators to retain records for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated. If no application is to be filed or if the application is not approved, records must be kept for 2 years after the investigation is discontinued and the FDA is notified.

ICH E6(R3)

The International Council for Harmonisation (ICH) Good Clinical Practice guideline, E6(R3) (on ACRP exams since July 15, 2026), requires the investigator/institution to retain the essential records for the required retention period in accordance with applicable regulatory requirements or until the sponsor informs the investigator/institution that these records are no longer needed, whichever is the longest (2.12.12). The sponsor informs the site in writing of the retention requirements and of when records are no longer needed (3.16.3(b)), and the site keeps the sponsor informed of who is responsible for the records, for example when the site closes or the investigator leaves (2.12.13). E6(R3) sets no fixed number of years; it replaced E6(R2)'s formula tied to marketing approvals in ICH regions.

Sponsor and Institutional Policies

Because tracking international marketing approvals is practically impossible for an individual clinical site, sponsors take on the responsibility of notifying the site when records can finally be destroyed. Consequently, clinical trial agreements (CTAs) typically stipulate that sites cannot destroy any records without written permission from the sponsor. Many sponsors mandate much longer retention periods. Furthermore, a hospital or university's own institutional policies might require permanent retention of certain medical records. The golden rule is: always follow the longest mandated retention period .

Essential Documents to Retain

The Investigator Site File (ISF) or Regulatory Binder contains the "Essential Documents" that must be archived. Key documents include:

Informed Consent Forms (ICFs): Original, signed, and dated ICFs for all subjects (including screen failures).

Source Documents: Hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries, and pharmacy dispensing records.

Case Report Forms (CRFs): Copies of all completed CRFs submitted to the sponsor.

Regulatory Documents: Form FDA 1572, IRB approval letters, investigator CVs, financial disclosure forms, and the Investigator's Brochure (IB).

Drug Accountability Records: Logs detailing the receipt, dispensing, and return or destruction of the investigational product.

Communication Logs: Correspondence with the sponsor, IRB, and monitors.

Best Practices for Archiving

When a trial is closed out, the active files are moved into long-term archiving. This transition must be handled meticulously by the CRC to ensure documents remain accessible and legible.

Environmental Controls

Whether archiving is managed on-site or at a third-party commercial storage facility, the environment must be controlled to prevent document degradation. This include:

Climate Control: Regulating temperature and humidity to prevent mold and paper decay.

Pest Control: Ensuring the facility is secure against rodents and insects.

Disaster Prevention: Utilizing fire-resistant cabinets, sprinkler systems (preferably dry-pipe), and storing boxes off the floor to mitigate water damage.

Security and Access Control

Archived records contain Protected Health Information (PHI) and proprietary sponsor data. Access must be strictly restricted to authorized personnel. If a regulatory inspector requests a document from an archived study, the site must be able to retrieve it promptly. Therefore, a robust indexing and tracking system is essential. The index should list the box contents, study number, PI name, date of archiving, and the anticipated destruction date.

Electronic Archiving

The industry is rapidly shifting toward electronic Trial Master Files (eTMF) and electronic investigator site files (eISF). When archiving electronic records, CRCs must ensure the media used (e.g., hard drives, cloud servers) is durable and that the files will remain readable as software evolves (e.g., saving files in standard formats like PDF/A). Additionally, electronic archives must be backed up, and access must be governed by strict authentication protocols, complying with 21 CFR Part 11 requirements. A copy can permanently replace an original essential record only if it is a certified copy: verified, by a dated signature or by generation through a validated process, to have the same information as the original, including relevant metadata (ICH E6(R3) C.2.9 and glossary).